Sugi Predict

Sugi Predict / Compounds / SCHEMBL15919123

SCHEMBL15919123

SCHEMBL15919123

O=C(O)CC[C@H](NC(=O)CCN1C(=O)C=CC1=O)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 3/20 0.49
▸ NAALAD2 Q9Y3Q0 3/20 0.49
▸ RIMKLA Q8IXN7 1/20 0.49
▸ PTGS1 P23219 4/20 0.47
▸ PTGS2 P35354 4/20 0.47
▸ FNTA P49354 4/20 0.46
▸ FNTB P49356 4/20 0.46
▸ GNPAT O15228 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16273731 1.00 FOLH1 (0.49) FOLH1NAALAD2RIMKLAPTGS1PTGS2
SCHEMBL16156903 0.92 PTGS1 (0.53) FOLH1NAALAD2RIMKLAPTGS1PTGS2
SCHEMBL22311921 0.89 PTGS1 (0.61) FOLH1NAALAD2RIMKLAPTGS1PTGS2
SCHEMBL17986401 0.89 MMP12 (0.46) FOLH1NAALAD2RIMKLAPTGS1PTGS2
SCHEMBL22311918 0.87 FOLH1 (0.50) FOLH1NAALAD2RIMKLAPTGS1PTGS2
SCHEMBL22311924 0.87 FNTA (0.47) PTGS1PTGS2FNTAFNTBGAA
SCHEMBL22311947 0.85 FOLH1 (0.44) FOLH1
SCHEMBL15919185 0.85 FOLH1 (0.44) FOLH1
SCHEMBL19903763 0.85 FOLH1 (0.44) FOLH1
SCHEMBL22311946 0.85 FOLH1 (0.44) FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10947289-B2 Glyco-modified atrial natriuretic peptide DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-03-16 — — US disclosed
US-20210040170-A1 GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-02-11 — — US disclosed
EP-2949665-B1 GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE DAIICHI SANKYO CO LTD (JP) 2018-02-28 — — EP disclosed
US-20160017015-A1 GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-21 — — US disclosed
US-20160017015-A1 GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-21 — — US disclosed
EP-2949665-A1 GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-12-02 — — EP disclosed
WO-2014115797-A1 GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE 第一三共株式会社 (JP) 2014-07-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10947289-B2 Glyco-modified atrial natriuretic peptide NPPA, NPR1, NPR3 FOLH1 2196/4885NAALAD2 719/4885RIMKLA 3684/4885
US-20210040170-A1 GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE NPPA, NPR1, NPR3 FOLH1 2196/4885NAALAD2 719/4885RIMKLA 3684/4885
US-20160017015-A1 GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE NPPA, NPR1, NPR3 FOLH1 2196/4885NAALAD2 719/4885RIMKLA 3684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.